A 64-year-old with T2D and obesity starts tirzepatide; after dose escalation, he reports GI symptoms. Which strategy aligns with guidance?...

Question

A 64-year-old with T2D and obesity starts tirzepatide; after dose escalation, he reports GI symptoms. Which strategy aligns with guidance?

Accepted Answer

Maintain dose despite intolerable symptoms

Answer

Reduce to prior tolerated dose and slow re-escalation

Answer

Switch to DPP-4 and continue tirzepatide

Answer

Stop all therapy

Answer

Add metoclopramide indefinitely

us-abfm MCQ (SBA): GLP-1/GIP Agonist Titration